[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336890-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-336890-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","a-10-gene-signature-to-predict-the-prognosis-of-early-stage-triple-negative-breast-cancer-original-article-report","A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer - Original Article - Report","","Triple-negative breast cancer (TNBC) is a difficult subtype with poorer outcomes, and early-stage patients still lack a validated biomarker for reliable prognostic prediction. This study analyzes RNA-sequencing gene expression profiles from 184 TNBC patients, split into training and validation cohorts. Weighted gene expression identifies a 10-gene signature that stratifies risk for invasive disease-free survival with high sensitivity, specificity, and accuracy. The signature is validated across institutions and supported by meta-analysis of pathway relevance, remaining an independent factor in multivariate analyses.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-10-gene-signature-to-predict-the-prognosis-of-early-stage-triple-negative-breast-cancer-original-article-report/336890/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-10-gene-signature-to-predict-the-prognosis-of-early-stage-triple-negative-breast-cancer-original-article-report/336890.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What clinical problem does the study address in early-stage TNBC?","Question",{"text":62,"@type":63},"The study targets the lack of a validated biomarker that can accurately predict prognosis for early-stage triple-negative breast cancer patients.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was the 10-gene signature developed and validated?",{"text":67,"@type":63},"Researchers used RNA sequencing of tumor gene expression profiles from 184 patients to derive a weighted 10-gene signature, then validated the signature in an independent cohort from another institution.",{"name":69,"@type":60,"acceptedAnswer":70},"What evidence shows the signature predicts invasive disease-free survival effectively?",{"text":71,"@type":63},"The 10-gene signature achieved high sensitivity, specificity, and accuracy for invasive disease-free survival, and it remained the only independent factor in multivariate analysis compared with other candidate biomarkers.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},336890,1790243353,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","pISSN 1598-2998, eISSN 2005-9256  \n\n| [https://doi.org/10.4143/crt.2024.100](https://doi.org/10.4143/crt.2024.100) Cancer Res Treat. 2024;56(4):1113-1125\u003Cbr>\u003Cbr>Original Article\u003Cbr>A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer\u003Cbr>Chang Min Kim1,2 , Kyong Hwa Park3 , Yun SukYu1 , Ju Won Kim3 , Jin Young Park1 , Kyunghee Park4 , Jong-HanYu5 , Jeong Eon Lee5 , Sung Hoon Sim6 , Bo Kyoung Seo7 , Jin Kyeoung Kim2 , Eun SookLee6 , Yeon Hee Park8 , Sun-Young Kong9,10\u003Cbr>1CbsBioscience. Inc., Daejeon, 2Department of Pharmacy, College of Pharmacy, CHA University, Seongnam, 3Division of Medical Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, 4Samsung Genome Institute, Samsung Medical Center, Seoul, 5Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 6Breast Cancer Center, National Cancer Center, Goyang, 7Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 8Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 9Targeted Therapy Branch, Research Institute, National Cancer Center, Goyang, 10Department of Laboratory Medicine, Hospital, National Cancer Center, Goyang, Korea |  |\n| --- | --- |\n| Purpose Triple-negative breast cancer (TNBC) is a particularly challenging subtype of breast cancer, with a poorer prognosis compared to other subtypes. Unfortunately, unlike luminal-type cancers, there is no validated biomarker to predict the prognosis of patients with early-stage TNBC. Accurate biomarkers are needed to establish effective therapeutic strategies.\u003Cbr>Materials and Methods In this study, we analyzed gene expression profiles of tumor samples from 184 TNBC patients (training cohort, n=76; validation cohort, n=108) using RNA sequencing.\u003Cbr>Results By combining weighted gene expression, we identified a 10-gene signature (DGKH, GADD45B, KLF7, LYST, NR6A1, PYCARD, ROBO1, SLC22A20P, SLC24A3, andSLC45A4) that stratified patients by risk score with high sensitivity (92.31%), specificity (92.06%), and accuracy (92.11%) for invasive disease-free survival. The 10-gene signature was validated in a separate institution cohort and supported by meta-analysis for biological relevance to well-known driving pathways in TNBC. Furthermore, the 10-gene signature was the only independent factor for invasive disease-free survival in multivariate analysis when compared to other potential biomarkers of TNBC molecular subtypes and T-cell receptor β diversity. 10-gene signature also further categorized patients classified as molecular subtypes according to risk scores.\u003Cbr>Conclusion Our novel findings may help address the prognostic challenges inTNBC and the 10-gene signature could serve as a novel biomarker for risk-based patient care.\u003Cbr>Key words Triple-negative breast neoplasms, Biomarkers, Prognostic diagnosis, Gene signature |  |\n| Introduction | on mRNA expression, significant efforts have been made to elucidate subtypes of the highly heterogeneous cancer using |\n| Breast cancer is the most common cancer among women | new technologies [8-10] . Multi-omic analyses and new sys- |\n| and is increasing globally, including in Korea [1-3] . Recent | tematic approach were utilized for the better classification |\n| research has led to significant advances in new therapeu- | and more sophisticated therapeutic strategy in the recent |\n| tics and precision medicine, and active clinical applications | studies [11-16] . Nonetheless, only a few biomarkers have |\n| of the novel approaches resulted in improved prognosis of | been identified to accurately predict prognosis and guide |\n| patients with breast cancer [4-6] . | treatment decisions [17] . |\n| Despite these advances, triple-negative breast cancer | In this study, we aimed to develop a clinically applicable |\n| (TNBC) remains the most challenging su","cbCail9gdzsp8Cxd","https://ap.wps.com/l/cbCail9gdzsp8Cxd","pdf",1738617,13,"English","# Purpose\n# Materials and Methods\n## Patients and specimens\n# Results\n# Conclusion\n# Key words","[{\"question\":\"What clinical problem does the study address in early-stage TNBC?\",\"answer\":\"The study targets the lack of a validated biomarker that can accurately predict prognosis for early-stage triple-negative breast cancer patients.\"},{\"question\":\"How was the 10-gene signature developed and validated?\",\"answer\":\"Researchers used RNA sequencing of tumor gene expression profiles from 184 patients to derive a weighted 10-gene signature, then validated the signature in an independent cohort from another institution.\"},{\"question\":\"What evidence shows the signature predicts invasive disease-free survival effectively?\",\"answer\":\"The 10-gene signature achieved high sensitivity, specificity, and accuracy for invasive disease-free survival, and it remained the only independent factor in multivariate analysis compared with other candidate biomarkers.\"}]","A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer - Original Article - Report | PDF",1790016976,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3921125f9c51170509a70afed3823c6.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0adb20f24fa53e57c3f088f6de36562b.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c51adccefd450d65ca5b6634cadfa8a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47e1a3c7b6f6c21c07b0fb7899dedea6.webp",980,1306]